X0508 4 2024-01-03 0 0001607678 Viking Therapeutics, Inc. VKTX 0001614578 Lian Brian C/O VIKING THERAPEUTICS, INC. 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 1 1 0 0 President & CEO 0 Common Stock, par value $0.00001 per share 2024-01-03 4 A 0 150000 0.00 A 2359074 D Common Stock, par value $0.00001 per share 2024-01-03 4 F 0 108525 17.40 D 2250549 D Common Stock, par value $0.00001 per share 2024-01-03 4 A 0 160000 0.00 A 2410549 D Common Stock, par value $0.00001 per share 2024-01-03 4 F 0 106115 17.40 D 2304434 D Common Stock, par value $0.00001 per share 2024-01-04 4 F 0 39552 18.58 D 2264882 D Stock Option (Right to Buy) 17.40 2024-01-03 4 A 0 360000 0.00 A 2025-01-03 2034-01-03 Common Stock 360000 360000 D The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2022, 33.33% of which vested on January 3, 2024 upon the achievement of a non-financial performance goal. Includes 6,421 shares acquired on May 19, 2023 and 4,690 shares acquired on November 20, 2023 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units. Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. 25% of the shares subject to the option will vest on each anniversary of the grant date. /s/ Michael Morneau, as Attorney-in-Fact 2024-01-04